Wednesday, November 08, 2017 2:24:51 PM
If we don't get something started on ARS pivotal trial this year or first quarter latest next year, dilution will come again soon after. Obviously a partnership or something else would change that as well.
The grant covers a significant portion of the CLI trial, but not all. And with Pluristem directly only receiving $3.4 million directly, doesn't keep us afloat much longer. And I can't, based on previous trials etc., see this trial moving quickly.
I believe so much of the future of this company, or stock price and future dilution concerns at least, rests entirely on ARS. I am astonished it has taken this long already. But if the U.S. wants it, budget or no budget they will get it.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM